GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 41
- Registration Number
- NCT00836914
- Locations
- 🇦🇹
Vienna Challenge Chamber, Vienna, Austria
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 162
- Registration Number
- NCT00832507
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸The Lindner Clinical Trial Center, Cincinnati, Ohio, United States
Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy
- Conditions
- Coronary Artery DiseasePolyneuropathyPainPeripheral Nervous System Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2014-06-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 5
- Registration Number
- NCT00832572
- Locations
- 🇺🇸
Cardiovascular Institute of the South Clinical Research Corporation, Houma, Louisiana, United States
Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patients With Bronchiectasis
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2014-03-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 89
- Registration Number
- NCT00805025
Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2009-10-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 12
- Registration Number
- NCT00800579
- Locations
- 🇦🇺
Nucleus Network Ltd., Melbourne, Victoria, Australia
Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: FTI, AZLIDrug: Placebo, AZLI
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2013-12-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 120
- Registration Number
- NCT00794586
Study of Ambrisentan in Participants With Pulmonary Hypertension
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 140
- Registration Number
- NCT00777920
- Locations
- 🇺🇸
Atlanta Institute for Medical Research, Inc., Atlanta, Georgia, United States
🇺🇸Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸University of Pittsburgh Medical Center Presbyterian, Pittsburgh, Pennsylvania, United States
ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2011-11-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 85
- Registration Number
- NCT00772902
- Locations
- 🇪🇸
Gilead Sciences, Madrid, Spain
(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 494
- Registration Number
- NCT00768300
- Locations
- 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2011-07-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 274
- Registration Number
- NCT00757237